Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INT068
MIFTS: 64

Intestinal Disease

Categories: Infectious diseases, Gastrointestinal diseases, Fetal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Intestinal Disease

About this section

MalaCards integrated aliases for Intestinal Disease:

Name: Intestinal Disease 12 15
Intestinal Diseases 44 73

Classifications:

MalaCards categories:
Global: Infectious diseases Fetal diseases Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:5295
ICD9CM 35 569.9
MeSH 44 D007410
NCIt 50 C26801
UMLS 73 C0021831
Sources

Summaries for Intestinal Disease

About this section
Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to crohn's disease and inflammatory bowel disease, and has symptoms including anal or rectal pain, constipation and diarrhea. An important gene associated with Intestinal Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Influenza A. The drugs Lansoprazole and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include the intestine, colon and liver, and related phenotypes are homeostasis/metabolism and cardiovascular system

Sources

Related Diseases for Intestinal Disease

About this section

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 crohn's disease 32.0 ATG16L1 CRP IL10 IL1B IL6 NOD2
2 inflammatory bowel disease 30.9 AREG ATG16L1 CRP DEFB4A IL10 IL1B
3 mature b-cell neoplasm 30.7 SDC1 TLR9 TP53
4 peptic ulcer disease 30.5 GHRL IL10 IL1B TNF
5 gastritis 30.5 AREG DEFB4A GHRL IL1B
6 arthritis 30.3 IL10 IL1B IL6 TNF
7 common variable immunodeficiency 30.3 IL10 IL6 TLR9 TNF
8 toxoplasmosis 30.2 IL10 IL1B IL6 TLR9 TNF
9 gastroenteritis 30.1 CRP IL10 IL1B IL6 TNF
10 peritonitis 30.1 CRP IL10 IL1B IL6 TNF
11 osteoporosis 29.8 CRP IL1B IL6 TNF TRPV1
12 asthma 29.6 AREG IL10 IL1B IL6 TLR9 TNF
13 colitis 29.3 ATG16L1 IL10 IL1B IL6 NOD2 TFF3
14 alpha-heavy chain disease 11.5
15 punctate inner choroidopathy 11.2 IL10 TNF
16 tropical endomyocardial fibrosis 11.1 IL10 TNF
17 lichen disease 11.1 TLR9 TNF TP53
18 protozoal dysentery 11.1
19 scorpion envenomation 11.1 IL6 TNF
20 anca-associated vasculitis 11.1 GHRL IL6 TNF
21 alpha chain disease 11.1
22 mucocutaneous leishmaniasis 11.1 IL10 TLR9 TNF
23 cellulitis 11.1 CRP DEFB4A TNF
24 eye lymphoma 11.1 IL10 IL6 TLR9
25 meninges sarcoma 11.1 GCG TP53
26 coccidiosis 11.1 IL10 TLR9 TNF
27 crohn's colitis 11.1 IL1B NOD2 TNF
28 orofacial granulomatosis 11.1 IL10 NOD2 TNF
29 dental pulp disease 11.1 IL1B TNF TRPV1
30 vaginal disease 11.1 DEFB4A IL1B IL6
31 burning mouth syndrome 11.1 IL6 TNF TRPV1
32 vaginitis 11.0 DEFB4A IL1B IL6
33 hypersensitivity reaction type iv disease 11.0 NOD2 TLR9 TNF
34 streptococcal meningitis 11.0 CRP NOD2 TNF
35 cold agglutinin disease 11.0 CRP IL6
36 atrophic gastritis 11.0 GHRL IL1B TP53
37 nasal cavity disease 11.0 IL10 TLR9 TRPV1
38 lichen planus 11.0 DEFB4A TLR9 TNF TP53
39 blau syndrome 11.0 IL1B NOD2 TNF
40 viral pneumonia 11.0 CRP IL6 TLR9
41 middle ear disease 11.0 IL1B TLR9 TNF
42 rosacea 11.0 IL6 TNF TRPV1
43 laryngitis 11.0 IL1B IL6 TNF
44 acute graft versus host disease 11.0 IL10 NOD2 TNF
45 prediabetes syndrome 11.0 CRP GCG IL6
46 listeriosis 11.0 IL10 IL6 TNF
47 transverse myelitis 11.0 IL10 IL6 TNF
48 aseptic meningitis 11.0 IL10 IL1B TNF
49 funisitis 11.0 IL10 IL1B IL6
50 acute vascular insufficiency of intestine 11.0 IL1B IL6 TNF

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Ischemic Heart Disease Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease
Sources

Symptoms & Phenotypes for Intestinal Disease

About this section

UMLS symptoms related to Intestinal Disease:


anal or rectal pain, constipation, diarrhea, signs and symptoms, digestive

MGI Mouse Phenotypes related to Intestinal Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 TRPV1 UCN EDNRB AREG GHRL ATG16L1
2 cardiovascular system MP:0005385 10.24 TP53 TRPV1 IL10 CRP EDNRB AREG
3 cellular MP:0005384 10.22 TP53 TRPV1 IL10 EDNRB HPS4 ATG16L1
4 digestive/alimentary MP:0005381 10.2 EDNRB AREG GHRL ATG16L1 IL10 TP53
5 growth/size/body region MP:0005378 10.18 TP53 TRPV1 IL10 EDNRB AREG HPS4
6 hematopoietic system MP:0005397 10.15 EDNRB AREG HPS4 ATG16L1 IL10 NOD2
7 endocrine/exocrine gland MP:0005379 10.13 TP53 IL10 EDNRB AREG GHRL ATG16L1
8 immune system MP:0005387 10.1 TRPV1 EDNRB AREG ATG16L1 IL10 CRP
9 integument MP:0010771 9.85 TRPV1 EDNRB AREG HPS4 IL10 TP53
10 neoplasm MP:0002006 9.56 TRPV1 EDNRB IL10 TP53 SDC1 IL1B
11 vision/eye MP:0005391 9.23 TP53 IL10 EDNRB AREG HPS4 ATG16L1
Sources

Drugs & Therapeutics for Intestinal Disease

About this section

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 103577-45-3 3883
2
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
3
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 23994
4
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
5
Ticlopidine Approved Phase 4,Phase 2,Not Applicable 55142-85-3 5472
6
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2 95058-81-4 60750
7
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 17902-23-7 5386
8
Clopidogrel Approved Phase 4,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
9
Ceftriaxone Approved Phase 4,Not Applicable 73384-59-5 5479530 5361919
10
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9004-61-9 53477741
11
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
12
Ertapenem Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 153832-46-3 150610
13
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2216-51-5 16666
14
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
15
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
16
Tetracycline Approved, Vet_approved Phase 4,Phase 2,Not Applicable 60-54-8 5353990
17
Nicotine Approved Phase 4,Phase 3,Not Applicable 54-11-5 942 89594
18
Famotidine Approved Phase 4,Phase 3,Phase 1,Not Applicable 76824-35-6 3325
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
20
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
21
Alvimopan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 156053-89-3 5488548
22
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
23
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 169590-42-5 2662
24
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128-13-2 31401
25
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 114-07-8 12560
26
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
27
Ifosfamide Approved Phase 4,Phase 2,Phase 1 3778-73-2 3690
28
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
29
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
30
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-81-5 753
31
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
32
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
33
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
34
Mannitol Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 69-65-8 453 6251
35
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
36
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
37
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81103-11-9 84029
38
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73590-58-6 4594
39
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
40
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
41
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
42
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
43
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
44
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2 2030-63-9 2794
45
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Not Applicable 82419-36-1 4583
46
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Amitriptyline Approved Phase 4,Phase 2,Phase 3 50-48-6 2160
49
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
50
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290

Interventional clinical trials:

(show top 50) (show all 8767)
# Name Status NCT ID Phase Drugs
1 Single-Operator Versus Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
2 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
3 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
4 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
5 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
6 Double- Versus Single-balloon Enteroscopy for Obscure Small-bowel Bleeding Unknown status NCT01176864 Phase 4
7 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
8 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
9 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
10 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
11 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
12 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
13 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
14 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
15 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
16 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
17 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
18 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
19 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
20 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
21 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
22 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
23 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
24 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
25 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
26 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
27 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
28 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
29 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
30 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
31 A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis Unknown status NCT02425852 Phase 4 Azathioprine;Infliximab;Prednisolone;Hydrocortisone
32 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
33 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
34 Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB) Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
35 Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer Unknown status NCT00471029 Phase 4 esomeprazole
36 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
37 Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients Unknown status NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
38 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
39 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
40 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
41 A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula Unknown status NCT02423330 Phase 4
42 Helicobacter Pylori Empiric Treatment in Ulcer Bleeding Unknown status NCT00687336 Phase 4
43 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
44 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
45 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
46 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
47 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
48 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
49 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
50 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Sources

Genetic Tests for Intestinal Disease

About this section
Sources

Anatomical Context for Intestinal Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

19
The Intestine

MalaCards organs/tissues related to Intestinal Disease:

41
Colon, Liver, Testes, Lung, T Cells, Small Intestine, Lymph Node
Sources

Publications for Intestinal Disease

About this section

Articles related to Intestinal Disease:

(show top 50) (show all 384)
# Title Authors Year
1
Toxic Causes of Intestinal Disease in Horses. ( 29397222 )
2018
2
Socioeconomic status and infectious intestinal disease in the community: a longitudinal study (IID2 study). ( 29016791 )
2018
3
Altered gut microbiota associated with intestinal disease in grass carp (Ctenopharyngodon idellus). ( 29777414 )
2018
4
Identifying free-text features to improve automated classification of structured histopathology reports for feline small intestinal disease. ( 29188759 )
2018
5
Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease. ( 29778465 )
2018
6
Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )
2018
7
Surgical Management of Abomasal and Small Intestinal Disease. ( 29249602 )
2018
8
Avian Influenza Virus Subtype H9N2 Affects Intestinal Microbiota, Barrier Structure Injury, and Inflammatory Intestinal Disease in the Chicken Ileum. ( 29783653 )
2018
9
Socioeconomic status is associated with symptom severity and sickness absence in people with infectious intestinal disease in the UK. ( 28645256 )
2017
10
Recurrent diarrhoea in a renal transplant recipient: Early immunoproliferative small intestinal disease may be missed if not considered. ( 28205353 )
2017
11
Mechanisms and function of autophagy in intestinal disease. ( 29130415 )
2017
12
An Ontology to Improve Transparency in Case Definition and Increase Case Finding of Infectious Intestinal Disease: Database Study in English General Practice. ( 28958989 )
2017
13
Systematic review: exercise-induced gastrointestinal syndrome-implications for health and intestinal disease. ( 28589631 )
2017
14
Whole-Blood Taurine Concentrations in Cats With Intestinal Disease. ( 28626960 )
2017
15
Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease. ( 28622393 )
2017
16
Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. ( 28194152 )
2017
17
Clinical outcome after enteroscopy for small bowel angioectasia bleeding: A Korean Associateion for the Study of Intestinal Disease (KASID) multiceter study. ( 27356264 )
2017
18
Do surveillance intervals in patients with more than five adenomas at index colonoscopy be shorter than those in patients with three to four adenomas? A Korean Association for the Study of Intestinal Disease study. ( 27862272 )
2017
19
Sopping up IL-22 drives intestinal disease. ( 27846535 )
2016
20
Thromboembolism in Dogs with Protein-Losing Enteropathy with Non-Neoplastic Chronic Small Intestinal Disease. ( 27841681 )
2016
21
A new anastomosis technique for intestinal diseases with proximal dilated segments. ( 27046984 )
2016
22
18F-FDG PET imaging for identifying the dynamics of intestinal disease caused by SFTSV infection in a mouse model. ( 26700962 )
2016
23
Intestinal Organoids: New Frontiers in the Study of Intestinal Disease and Physiology. ( 27632431 )
2016
24
Risk of Advanced Colorectal Neoplasia According to the Number of High-Risk Findings at Index Colonoscopy: A Korean Association for the Study of Intestinal Disease (KASID) Study. ( 26809871 )
2016
25
Prevalence and risk factors for development of hemorrhagic gastro-intestinal disease in veterinary intensive care units in the United Kingdom. ( 26641416 )
2016
26
Estimating the Incidence of Acute Infectious Intestinal Disease in the Community in the UK: A Retrospective Telephone Survey. ( 26807916 )
2016
27
Immunoproliferative Small Intestinal Disease Associated with Overwhelming Polymicrobial Gastrointestinal Infection with Transformation to Diffuse Large B-cell Lymphoma. ( 26903604 )
2016
28
Keratins Are Altered in Intestinal Disease-Related Stress Responses. ( 27626448 )
2016
29
Old Friends in New Places: Exploring the Role of Extraintestinal E.A coli in Intestinal Disease and Foodborne Illness. ( 25917531 )
2015
30
Myocardial Function by Two-Dimensional Speckle Tracking Echocardiography and Activin A May Predict Mortality in Patients with Carcinoid Intestinal Disease. ( 26111973 )
2015
31
Defective goblet cell exocytosis contributes to murine cystic fibrosis-associated intestinal disease. ( 25642775 )
2015
32
Cognitive Function of Patients with Crohn's Disease is Associated with Intestinal Disease Activity. ( 26398711 )
2015
33
Inflammatory, immunological, and intestinal disease biomarkers in Chinese Shar-Pei dogs with marked hypocobalaminemia. ( 25525135 )
2015
34
Parental Nutrition-Associated Liver Disease in Extremely Low Birth Weight Infants with Intestinal Disease. ( 25728615 )
2015
35
Feasibility of detecting small intestinal disease by FDG-PET/CT. ( 26070746 )
2015
36
P578. Assessment of satisfaction with healthcare in patients with inflammatory bowel disease: An Online Korean Association for the Study of Intestinal Disease (KASID) Survey. ( 25718076 )
2015
37
Expression of PGP 9.5 by enteric neurons in horses and donkeys with and without intestinal disease. ( 24444819 )
2014
38
Draft Genome Sequence of Campylobacter coli Strain IPSID-1 Isolated from a Patient with Immunoproliferative Small Intestinal Disease. ( 24625865 )
2014
39
Contributions of NanI Sialidase to Caco-2 Cell Adherence by Clostridium perfringens Type A and C Strains Causing Human Intestinal Disease. ( 25135687 )
2014
40
Clinical features and predictors of clinical outcomes in Korean patients with Crohn's disease: A Korean Association for the Study of Intestinal Diseases multicenter study. ( 23981141 )
2014
41
Immunoproliferative small intestinal disease: a report of 6 cases. ( 26349179 )
2014
42
Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. ( 24447345 )
2014
43
Campylobacter coli cultured from the stools of a patient with immunoproliferative small intestinal disease. ( 24438451 )
2014
44
Indoleamine 2,3 dioxygenase in intestinal disease. ( 23283180 )
2013
45
Immunoproliferative small intestinal disease presented with ascites and edema. ( 24558774 )
2013
46
Role of damage control enterostomy in management of children with peritonitis from acute intestinal disease. ( 24469480 )
2013
47
The second study of infectious intestinal disease (IID2): increased rates of recurrent diarrhoea in individuals aged 65 years and above. ( 24219653 )
2013
48
Diabetes is predominantly an intestinal disease. ( 24251223 )
2013
49
Bowel-associated dermatosis-arthritis syndrome: another cutaneous manifestation of inflammatory intestinal disease. ( 22640167 )
2013
50
Osteoarticular manifestations: specific treatments and/or treating intestinal disease? ( 24030233 )
2013
Sources

Variations for Intestinal Disease

About this section

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1 Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1 Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease
Sources

Expression for Intestinal Disease

About this section
Search GEO for disease gene expression data for Intestinal Disease.
Sources

Pathways for Intestinal Disease

About this section

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 12.95 ATG16L1 IL10 IL1B IL6 NOD2 TLR9
2
Influenza A 37
Show member pathways
 12.76 IL1B IL6 TLR9 TNF TP53
3
NF-KappaB Family Pathway 64
Show member pathways
 12.67 AREG IL1B IL6 TLR9 TNF
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.55 IL10 IL1B IL6 TNF TP53
5
Th17 cell differentiation 37
Show member pathways
 12.41 IL10 IL1B IL6 NOD2 TNF
6
T cell receptor signaling pathway 37
Show member pathways
 12.38 IL10 IL1B IL6 TNF
7
IL-17 Family Signaling Pathways 65
Show member pathways
 12.3 DEFB4A IL1B IL6 TNF
8
Folate Metabolism 1
Show member pathways
 12.28 CRP IL1B IL6 TNF TP53
9
Toll Comparative Pathway 64
Show member pathways
 12.24 IL1B IL6 TNF TP53
10
Th1 Differentiation Pathway 65
Show member pathways
 12.18 IL10 IL1B IL6 TLR9 TNF
11
Colorectal Cancer Metastasis 64
12.16 IL6 TLR9 TNF TP53
12
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.15 IL10 IL1B IL6 TNF
13
C-type lectin receptor signaling pathway 37
Show member pathways
 12.13 IL10 IL1B IL6 TLR9 TNF
14
Bacterial infections in CF airways 22
Show member pathways
 12.09 DEFB4A IL1B IL6 TLR9 TNF
15
Fluid shear stress and atherosclerosis 37
12.06 IL1B SDC1 TNF TP53
16
Spinal Cord Injury 1
11.99 IL1B IL6 TNF TP53
17
Tuberculosis 37
11.99 IL10 IL1B IL6 NOD2 TLR9 TNF
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.96 IL10 IL6 SDC1 TNF